In earlier studies, the anti-inflammatory and antioxidant abilities of Luteolin have been identified as responsible for the effectiveness of Luteolin in colon cancer and the complications associated with it, particularly the decreasing effect on the expressions of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) [42]. This evidence concerns the gene PTGS2 and colonic neoplasm.